Status:
UNKNOWN
Predictive Value of Infarction Volume on Hemorrhagic Transformation in Ischemic Stroke/TIA With Non-valve Atrial Fibrillation(NVAF) Patients Using Rivaroxaban
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborating Sponsors:
Bayer
Taizhou Hospital
Conditions:
Cerebrovascular Stroke
Intracranial Hemorrhages
Eligibility:
All Genders
18+ years
Brief Summary
This study was aimed at patients with newly diagnosed stroke / TIA associated with nonvalvular atrial fibrillation. We will observe the effect of early using rivaroxaban anticoagulation on hemorrhagic...
Eligibility Criteria
Inclusion
- Male or female, age≥18;
- Were newly diagnosed asischemic stroke/TIA concomitant NVAF;
- Prescribedand accept Rivaroxaban;
- Sign thewritten informed consent.
Exclusion
- Renal impairment (CrCl\<15 ml/min) or severe hepatic impairment.
- Significant hemorrhagic transformation (parenchymal hematoma type I or type II by the ECASS definition).
- Stroke or TIA caused by large artery atherosclerosis
- Planned major surgery or invasive intervention
- Active internal bleeding
- Malignancy or other serious medical conditions with a life expectancy \<6 months
- Allergery to Rivaroxaban
- Pregnancy or breast-feeding
Key Trial Info
Start Date :
January 18 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT03772457
Start Date
January 18 2019
End Date
December 31 2024
Last Update
April 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310009